Comparative Pharmacology
Head-to-head clinical analysis: TRI NORINYL 21 DAY versus TRI SPRINTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRI NORINYL 21 DAY versus TRI SPRINTEC.
TRI-NORINYL 21-DAY vs TRI-SPRINTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects, increases viscosity of cervical mucus, alters endometrial morphology, and inhibits ovulation.
Combination of ethinyl estradiol and norgestimate suppresses gonadotropin release, inhibiting ovulation, and increases viscosity of cervical mucus to inhibit sperm penetration.
One tablet (35 mcg ethinyl estradiol, 0.5 mg norethindrone for 7 days, 1 mg norethindrone for 9 days, 0.5 mg norethindrone for 5 days) orally once daily for 21 days, then 7 days off. Start on first day of menstrual period or first Sunday after onset.
One tablet (0.035 mg ethinyl estradiol / 0.250 mg norgestimate) orally once daily for 21 days, followed by 7 days of placebo tablets. Repeat cycle.
None Documented
None Documented
Norethindrone: 5-14 hours; Ethinyl estradiol: 17-23 hours. Steady-state reached within 5-7 days; clinical relevance for missed dose timing and resumption of ovulation.
Norelgestromin: 28 hours; Ethinyl estradiol: 17 hours. Steady-state achieved within 7 days.
Renal: ~50-60% (as metabolites); Fecal: ~30-40% (via bile); unchanged drug <1%.
Renal: 50% (metabolites); Fecal: 35% (eliminated in bile); unchanged drug <1%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive